Clinical Trial Update: MSG Use With 18F-DCFPyL PET/CT Imaging [NA]

View source ↗

Summary

A completed clinical trial evaluating the use of monosodium glutamate (MSG) with 18F-DCFPyL PET/CT imaging in prostate cancer, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostate Cancer Metastatic Disease
• Prostatic Neoplasm

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Prostate Cancer, Prostate Cancer Metastatic | NA | Status: COMPLETED | Results posted: 2021-02-12